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1. Introduction  
Stereotactic Radiosurgery (SRS) is a technology that utilizes externally generated ionizing 
radiation to treat (a) defined target(s) in the head or spine without the need to make an 
incision. The target is defined by high-resolution stereotactic imaging. It uses multiple 
convergent beams aimed to the target. The beams deliver a maximal dose to the target (with 
precision of less than 1mm), while minimizing irradiation of the surrounding tissues. The 
treatment is performed in a single session. The procedure requires a multidisciplinary team 
consisting of a neurosurgeon, radiation oncologist and medical physicist. Technologies that 
are used to perform SRS include linear accelerators, particle beam accelerators and 
multisource Cobalt 60 units. In order to enhance precision, various devices may incorporate 
robotics and real time digital imaging. (Stereotactic Radiosurgery Task Force 
AANS/CNS/ASTRO, March 20, 2006).  
“Stereotactic Radiosurgery” was invented by the Swedish neurosurgeon Lars Leksell in 
1951. Since its introduction, stereotactic radiosurgery (SRS) has evolved from an 
investigational concept into a recognized neurosurgical procedure for the management of a 
wide variety of brain disorders. Currently, radiosurgery can be employed as an adjuvant or 
definite treatment modality for pituitary adenomas.  
The three major sources of radiation used today to perform SRS are the multi-source Cobalt 
60 units, modified linear accelerators and the particle beam accelerators. These machines 
provide extremely accurate targeting and precise treatment for brain tumors. They treat 
brain tumors and other cerebral conditions in a one-day treatment. The original system is 
the Gamma Knife® System (GKS). Its clinical efficacy has been well documented, with more 
than 550,312 cases treated worldwide by December 2009 providing the data for over 2,500 
publications in peer-reviewed medical literature. The GKS is ideal for tumors less than 3.5 
cm, and functional disorders of the brain.  
The modified linear accelerator (m-LINAC) based radiosurgery machines are prevalent 
throughout the world. The modified linear accelerator systems use similar principles as the 
GKS to treat the patient, but the source of the radiation is a linear accelerator. Modified 
Linear accelerator-based radiosurgery generally utilizes a stereotactic head-frame, floor-
stand and a 6-megavolt (MV) linear accelerator. The linear accelerator systems utilize 
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radiation beams that are redirected in many "arcs" centered over an isocenter to lessen the 
adverse effects on healthy tissue. These machines can perform radiosurgery on tumors 
smaller than 3.5cm in diameter with the same range of precision of the GKS. Most of the 
GKS and m-LINAC systems employ a stereotactic head frame (ring). The head frame allows 
a precise localization of the lesion to be treated. The head frame, which is attached to the 
skull with four small screws, ensures that the radiation beams are precisely targeted. The 
frame also prevents head motion during the treatment procedure, which ensures that only 
the target area receives the prescribed radiation. However, modern localization techniques 
using bony landmarks identified by diagnostic X-Rays system has allowed some systems of 
m-LINAC to avoid the use of the stereotactic head frame. One of the advantages of these 
systems is that patients can be treated over more than one day without the need of wearing 
a head frame over extended periods of time, and in a few special situations can treat tumors 
slightly larger than 3.5 cm in diameter with this hypofractionating technique. Another 
advantage of the m-LINAC system is that they can use Intensity-Modulated Radiation 
Therapy (IMRT) and Image Guided Radiotherapy (IGRT) dosimetries algorithms to treat 
critically located lesions. In IMRT, the intensity of the radiation beam is non-uniform (i.e., 
modulated) across the treatment field, rather than producing a single, uniform, intensity 
beam. When combining this technique with the imaging done in the pre-plan, it further 
improves the delivery of radiation. These systems can provide treatment to lesions outside 
the brain. 
A special type of m-LINAC is the CyberKnife® Robotic Radiosurgery System. It utilizes a 6 
MV compact linear accelerator mounted on a computer-controlled six-axis robotic 
manipulator that permits a wide range of beam orientations and takes advantage of 
intelligent robotics to enable the effective treatment of tumors in the brain and anywhere in 
the body. To date, an estimated over 80,000 patients have been treated with the 
CyberKnife® System and currently more than 50 percent of all CyberKnife® procedures in 
the United States are extra cranial.  
The proton beam radiosurgery systems employ a stream of protons to treat lesions. As of 
June 2011, there were a total of 37 proton therapy centers in Canada, China, England, 
France, Germany, Italy, Japan, Korea, Poland, Russia, South Africa, Sweden, Switzerland, 
and USA and more than 73,800 patients had been treated (Particle Therapy Co-Operative 
Group, 2011). One hindrance to universal use of the proton in cancer treatment is the size 
and cost of the cyclotron or synchrotron equipment necessary to produce the protons. 
The authors have used a modified linear accelerator-based system to provide radiosurgery 
treatment to pituitary adenomas. The initial radiosurgery system installed in 1999 was 
manufactured by Radionics®. In 2003 this system was upgraded to a Brain Lab System® 
that incorporated a multileaf collimator. 
2. The radiobiology of radiosurgery  
The basic principle of ionizing radiation is the creation of ions or free radicals in the 
irradiated tissues. This ions or free radicals interact with the cell’s molecules producing 
damage to them. The radiation dose is usually measured in grays, where one gray (Gy) is 
the absorption of one joule per kilogram of mass. These ions and radicals, which may be 
formed from the water and oxygen in the cell or from the tissue substance, can produce 
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irreparable damage to DNA, proteins, membranes, and lipids that can evolve into the cell's 
death. The radiation effects can be seen in the order of minutes to years (Figure 1).  
 
Fig. 1. Effects of Ionizing radiation over time. 
Radiation damages the cell’s structures of tumor cells as well of normal cells in the radiation 
beam path. Normal tissue, however, is generally more proficient repairing sublethal damage 
than tumors cells. In general terms, tumors cells have altered repair mechanisms tolerating 
less irradiation damage than normal cells. Cells require time to repair DNA damage and one 
of the normal responses of the cell is delaying the cell cycle, delaying G2 phase. In 
radiotherapy where daily treatments with sublethal doses of radiation are given for several 
days, the difference in proficiency to repair the damage between normal and tumoral tissues 
is essential. Therefore, the radiobiology of the cell cycle and differences in cell repair are of 
great importance for fractionated radiotherapy. In radiosurgery, were a lethal dose of 
radiation is given in a single treatment, the repairing capacity of different tissues play a less 
critical role. Radiosurgery in many instances activates the apoptosis cascade resulting in cell 
death. The rate of proliferation of cells can determine the response to radiation, resulting in 
increased sensitivity of endothelial, glial and subependymal cells. Vascular endothelial cell 
damage tends to produce vessels obliteration that could play a role in the death of tumor 
cells as well.  
The radiation doses prescribed for radiotherapy have been developed from decades of 
clinical experience. However, the radiobiological principles of multifraction treatments do 
not necessarily apply to high dose ionizing beams as used in radiosurgery. Radiosurgery 
specifies a precise delivery of a high single fraction dose of ionizing beams to a defined 
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target volume. Normal tissue is excluded from the target as much as possible and a steep 
dose gradient at the margin of the target volume assures that the surrounding tissue 
receives a minimal dosage. Therefore, repair capacity of normal tissue during treatment is 
less critical in radiosurgery. 
3. Pituitary adenomas 
Pituitary adenomas represent nearly 10-20% of all intracranial tumors. Multimodal 
treatment includes microsurgery, medical management, radiotherapy and radiosurgery. 
Pituitary adenomas are broadly classified into two groups—functioning (secretory) and 
nonfunctioning. Microsurgery is the primary recommendation for nonfunctioning and most 
of functioning adenomas, except for prolactinomas that are usually managed with 
dopamine agonist drugs. Long-term tumor control rates after microsurgery alone range 
from 50 to 80%. For both functioning and nonfunctioning pituitary adenomas, incomplete 
tumor resection or recurrence because of tumor invasion into surrounding structures (for 
example, the dura mater or cavernous sinus) is common. Postsurgical residual secretory 
adenoma results in the persistence of a hypersecretory state and the associated deleterious 
clinical features. Moreover, about 30% of patients require additional treatment after 
microsurgery for recurrent or residual tumors. In patients with recurrent or residual 
pituitary adenomas, treatment options include repeat resection, radiation therapy, medical 
management, and radiosurgery. More recently, radiosurgery has been established as a 
treatment option. Radiosurgery allows the delivery of prescribed dose with high precision 
strictly to the target and spares the surrounding tissues. Therefore, the risks of 
hypopituitarism, visual damage and vasculopathy are significantly lower. Furthermore, the 
latency of the radiation response after radiosurgery is substantially shorter than that of 
fractionated radiotherapy. 
4. Planning and technique 
All patients suspected of harboring a pituitary tumor should undergo a complete 
neurologic, ophthalmologic, endocrinologic, and radiologic work-up (Laws & Sheehan, 
2006; Laws & Thapar 1996). This includes formal visual fields, an acuity testing and a 
detailed fundoscopic examination. Each facet of the hypothalamic-pituitary-end organ axis 
should be assessed by an endocrinologist and re-assessed by the neurosurgeon. (Table 1) 
Evaluation of the sellar region is best accomplished by using a thin slice pre- and post-
contrast magnetic resonance (MR) imaging. When there is a contraindication to MR or is not 
available, a computed tomography (CT) imaging can be useful (Jagannathan et al., 2005; 
Kanter et al., 2005).  
If a patient has a neurological deficit attributable to an adenoma, surgery is the initial 
treatment of choice for all tumors except prolactinomas. Transsphenoidal microsurgery 
(endoscopic or microscopic) affords the best chance of rapid relief of mass effect and 
reduction in excessive hormone levels in patients with Cushing’s disease and acromegaly 
(Laws & Sheehan, 2006; Laws & Thapar 1996; Laws et al., 1985a, 1985b, 2000). This approach 
is associated with a low rate of complications in the hands of experienced neurosurgeons 
(Ciric, 1997). For this reason, tumors located in areas such as the sellar floor or sphenoid that 
can be safely accessed surgically should undergo surgical removal, with radiosurgery being 
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reserved for tumor residuals or recurrences. For tumors that cannot be removed completely 
depending on the size, location, and invasiveness of surrounding tissues by the tumor, one 
surgical goal could be to create a safe distance of 2 to 5 mm between the lesion and optic 
apparatus so that an adequate radiosurgery dose can be delivered to the adenoma with 
minimal risk of radiation injury to the optic pathways. 
 
Hormone Test Results and Additional Evaluations 
Prolactin 
function 
Serum Levels 
Elevated prolactin, usually with serum 
levels > 75 ng/ml 
Thyroid 
function 
Free thyroxine and thyroid 
stimulating hormone 
 
Adrenal 
function 
Morning fasting and afternoon 
serum cortisol and ACTH level. 
Salivary cortisol levels. 
In Cushing’s syndrome, a 24 h urine 
free cortisol and a dexamethasone 
suppression test. 
Growth 
Hormone 
(GH) 
Growth hormone and insulin-like 
growth factor (IGF)-1. 
Oral glucose tolerance test with growth 
hormone measurements for GH 
secreting tumors. 
Table 1. Minimal basic endocrine workup for pituitary adenomas. 
Patients harboring secretory pituitary tumors warrant a special consideration regarding 
radiosurgery pre-planning. Since 2000, several studies have documented that cessation of 
suppressive medication before radiosurgery is recommended to offer the best normalization 
of hormone values after the treatment (Landolt 2000a, 2000b; Pouratian et al., 2006; Pollock 
et al., 2007). The optimal time period to temporarily halt anti-secretory medications is 
unclear and class I evidence is sill unavailable to support temporary cessation of 
antisecretory medications as a standard of care.  
5. Radiosurgery procedure 
When medical and surgical treatments are not curative or cannot control the tumor growth 
or symptoms, radiosurgery needs to be considered. Prior to considering radiosurgery, the 
neurosurgeon and the radiation oncologist of the radiosurgery team evaluate the patient, 
both need to agree that radiosurgery is an optimal option. Then, the patient is scheduled for 
the procedure. On the day of the treatment or the day before, a MR study is obtained, with 3 
mm thick slices of the brain including the sella and skull base. On the day of treatment a 
stereotactic head frame is applied under local anesthesia and/or IV sedation. Subsequently, 
stereotactic CT scanning is performed with the CT scan localizer on. Three-millimeter thick 
slices are obtained throughout the entire head. The stereotactic CT scan and MR images are 
transferred to the treatment-planning computer. The CT scan and MR images are fused 
electronically. The tumor, optic apparatus and critical surrounding structures are delineated 
in the planning computer. (Figure 2) The plan is carefully examined and adjusted to 
generate the actual treatment plan, maximizing the dose delivery to the tumor and 
minimizing irradiation of the optic apparatus and the surrounding tissues.  
The radiation oncologist and the neurosurgeon review and approve the plan. Four or more 
sagittally oriented irradiation arcs are typically delivered using multileaf collimators. The 
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multileaf collimator is adjusted every 15 degrees to achieve a conformal treatment to the 
lesion. The head ring is removed on the same day of treatment. After a short observation 
period, the patient is discharged. Close clinical and radiological neuroimaging follow-up 
examination is arranged at appropriate intervals depending on the entity treated and the 
condition of the patient. 
 
Fig. 2. Radiosurgical planning which includes protection of important structures and 
inclusion of treatment area.  
6. Toxicity and side effects 
Like any other medical intervention radiosurgery has side effects. The main concern is 
radionecrosis of structures adjacent to the pituitary gland; optic apparatus, cranial nerves 
within the cavernous sinus, hypothalamus, brainstem and medial temporal lobes. The 
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toxicity of fractionated external beam radiotherapy is low; with 1.5% risk of radiation optic 
neuropathy (Brada et al., 1993; Tsang et al., 1994) and 0.2% risk of necrosis of normal brain 
structures (Becker et al., 2002). The most frequent late consequence of radiation is 
hypopituitarism likely to be primarily due to hypothalamic injury or primary pituitary 
gland injury. In patients with normal pituitary function around the time of radiotherapy, 
hormone replacement therapy is required in 20–40% of patients at 10 years. A rare late effect 
of radiation for pituitary adenoma is the development of second radiation-induced brain 
tumor. The reported frequency is in the region of 2% at 10–20 years (Brada et al., 
1992; Tsang et al., 1993; Erfurth et al., 2001). Although there is an increased incidence of 
cerebrovascular accidents and excess cerebrovascular mortality in patients with pituitary 
adenoma treated with radiation, the influence of radiation on its frequency is not well 
defined (Brada et al., 1999, 2002; Tomlinson et al., 2001; Erfurth et al., 2002). 
The radiation effects on the optic apparatus, other cranial nerves and brainstem are of 
critical importance. Most of the damage is thought to be a result of secondary damage of the 
endothelium of small vessels and protective Schwann cells or oligodendroglia. There is a 
difference in the tolerance of different cranial nerves; with sensory nerves (optic and 
acoustic) tolerating the least radiation. The nerves in the parasellar region, the facial nerves 
and the lower cranial nerves usually tolerate higher doses. Clinical experience suggests that 
these specialized sensory nerves do not show a great capacity to recover from injury. 
Although the precise dose tolerance of the cranial nerves is unclear, the anterior visual 
pathways seem to be the least radio-resistant, and single doses above 8 Gy should be 
avoided (Jagannathan et al., 2007; Leber et al., 1995, 1998). To minimize the risk of 
irradiation injuries to the optic apparatus, the distance between optic nerves and chiasm and 
the lesion being treated should be carefully assessed. A distance of 5 mm between the tumor 
and the optic apparatus is ideal, but a distance of as little as 2 mm may be acceptable. It 
appears that the risk may be related to the volume of the optic apparatus receiving the dose 
(Chen et al., 2001; Lim et al., 1998; Sheehan et al., 2000; Witt et al., 1998). However, a specific 
critical volume has not been agreed. This distance is critical to design a dose plan that 
delivers a lethal radiation dose to the tumor yet spare the optic apparatus. When all these 
precautions and considerations are taken care the patient is treated accordingly.  
7. Radiosurgery for pituitary adenomas 
The goals of radiosurgery for pituitary tumors are control of tumor growth, and in secretory 
adenomas to normalize hormonal hypersecretion. In addition to the above mention, these 
goals need to be carried out avoiding acute and delay radiation injury to neural structures 
and preventing secondary tumor formation.  
7.1 Non-secreting tumors 
In our experience of twelve patients treated for nonfunctioning pituitary tumors (with mean 
follow-up of 47 months), tumor volume decreased in three patients (25%), remained 
unchanged in eight (66%), and there was no increased in size. One patient was lost to 
follow-up. Regarding tumor control, eleven patients achieved tumor control (91%) except 
for the patient who was lost to follow-up. All of our patients were treated with LINAC 
Radiosurgery as secondary therapy. The average prescription peripheral dose (Gy) was 
15.8Gy with a range from 8 to 22.5Gy. This is similar to previously published data. The 
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median time of tumor shrinkage on MR-imaging was 12 months (range, 8-68 months) 
following radiosurgery. This is consistent with a recently published series that 
demonstrated pituitary adenomas were 90%, 80%, and 70% of their initial volume at 1, 2, 
and 3 years post-GK radiosurgery (Sheehan et al., 2002). Tumors involving the parasellar 
space require special consideration, as they would be otherwise untreatable.  
Most other contemporary series involving stereotactic radiosurgery for non-functioning 
tumors (Table 2) have demonstrated excellent control of tumor growth, with a mean tumor 
control rate of 95.6% (range, 87%–100%) (Hayashi et al., 1999; Losa et al., 2004; Mitsumori et 
al., 1998; Morky et al., 1999; Muramatsu et al., 2003; Pollock & Carpenter, 2003; Pollock et al., 
2008; Sheehan et al., 2002; Witt et al., 1998;).  
In patients with four or more years of follow-up, the reported mean control rate is 95% 
(range, 83–100%) (Yoon et al., 1998; Morky et al., 1999; Feigl et al., 2002; Hoybye et al., 2001; 
Ikeda et al., 2001; Kobayashi et al., 2002; Shin et al., 2000; Wowra et al., 2002). Some series 
have even demonstrated improvement in visual function following radiosurgery after 
shrinkage of the tumor (Abe et al., 2002; Chen et al., 2001; Hayashi et al., 2005; Yoon et al., 
1998). Nevertheless, prevention of tumor growth, without volume reduction, is still 
considered a radiosurgical goal. 
The CyberKnife (Accuray, Calif., USA), is a newer radiosurgical device that is mounted on a 
maneuverable robotic manipulator and tracks the target with the aid of real-time guidance 
(Adler et al., 1997; Chang et al., 1998). Early experience with the Cyberknife has been 
promising for nonfunctioning adenomas, with a growth control rate of 95%, and lower 
prescription doses (14–16 Gy) than described for the Gamma Knife, although long-term 
clinical follow-up is still lacking (Kajiwara et al., 2005). 
 
Authors and Year 
Radiosurgery 
Unit 
No. of 
Patients 
Mean/Median
FU (months)
Max 
Dose 
(Gy)
Tumor 
Margin 
Dose(Gy) 
Growth 
Control 
(%) 
Mitsumori, et al., 1998 LINAC 7 47 19 15 100 
Witt, et al., 1998 GK 24 32 38 19 94 
Yoon, et al., 1998 LINAC 8 49 21 17 96 
Hayashi, et al., 1999 GK 18 16 NR 20 92 
Mokry, et al., 1999 GK 31 21 28 14 98 
Sheehan, et al., 2002 GK 42 31 32 16 98 
Muramatsu, et al., 
2003 
LINAC 8 30 26.9 15 100 
Pollock & Carpenter, 
2003 
GK 33 43 36 16 97 
Losa, et al., 2004 GK 54 41 33 17 96 
Iwai 2004 GK 34 60  14 87 
Mingione 2006 GK 90 45  18.5 92 
Pollock 2008 GK 62 45  16 97 
Brau 2011* LINAC 12 47 21.7 15.8 91 
Table 2. Summary of cases treated with Radiosurgery on Non-functioning pituitary 
adenomas. (*Unpublished manuscript in writing) 
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7.2 Secretory tumors 
Most published results on radiosurgery for secretory adenomas have differed based on 
methodology, endocrine criteria for remission, the study population and length of follow-
up. Most series typically report a higher prescription (margin) dose to patients with 
functioning adenomas, with a range between 20 Gy and 25 Gy in most reports (Jagannathan 
et al., 2007; Kim et al., 1999a, 1999b; Pouratian et al., 2006). Because hormone normalization 
has been followed in some cases by relapse, we prefer the term ‘‘remission’’ to ‘‘cure.’’ 
7.2.1 Acromegaly 
In our experience of fifteen patients treated for acromegaly (with mean follow-up of 37.2 
months), tumor volume decreased in five patients (33.3%), remained unchanged in nine 
(60%), and there was one (6.6%) patient that showed an increase in tumor size. Tumor 
control was achieved in fourteen (93.3%) patients. All of our patients were treated with 
LINAC Radiosurgery as secondary therapy. The average prescription peripheral dose (Gy) 
was 19.4Gy with a range from 12 to 25Gy. In our experience, the rate of hormone 
normalization after radiosurgery for Acromegaly was seen in six (41.6%) patients. Hormone 
normalization in these five patients was observed at mean follow-up of 28 months. Tumor 
control was achieved in most patients correlating with hormone remission, except for one 
patient, which despite hormone remission there was a slight increase in tumor size. 
The most widely accepted guidelines for endocrine remission in acromegaly consist of a GH 
level less than 1 ng/ml in response to an oral glucose challenge and a normal serum IGF-1 
when matched for age [Giustina et al., 2000; Vance, 1998).  
Published remission rates following radiosurgery for acromegaly vary widely from 0% to 
100%, with the majority of patients achieving tumor growth control (Table 3) (Buchfelder et 
al., 1991; Cozzi et al., 2001; Freda, 2003; Fukuoka et al., 2001; Horvath et al., 1983; Landolt et 
al., 1998, 2000; Pouratian et al., 2006; Witt et al., 1998). Jezkova et al. reported a remission 
rate of 50% at 42 months follow-up in 96 patients with acromegaly who received  
 
Author and Year
RSx 
Unit 
Pt No
F/U 
(mos) 
Peripheral 
Dose (Gy) 
IGF-1 
Normalization (%) 
Tumor 
Control (%) 
Muramatsu,  
2003 
LINAC 4 30 15 50 100 
Attanasio 2003 GK 30 46 20 23 100 
Castinetti 2005 GK 82 49.5 12-40 40 NR 
Voges 2006 LINAC 64 54.3 15.3 49.8 97 
Jezkova 2007 GK 96 53.7 32 50 100 
Pollock 2007 GK 46 63 20 50 100 
Vik-Mo 2007 GK 53 66 26.5 58 89 
Losa 2008 GK 83 69 21.5 60.2 98 
Jagannathan 
2008 
GK 95 57 22 53 98 
Brau 2011* LINAC 15 37.2 19.4 41.6 93.3 
Table 3. Summary of cases treated with Radiosurgery for Acromegaly. (*Unpublished 
manuscript in writing) 
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radiosurgery (Jezkova et al., 2006). Nearly one-third of these patients, however, had 
radiosurgery as primary treatment, without surgical extirpation of the adenoma. Pollock et 
al., (2007) demonstrated a remission rate of 50% in 46 patients with a higher remission rate 
in patients who were off suppressive medications at the time of radiosurgery. Pollock’s 
group also stated that maximal radiosurgery effects may be delayed up to 5 years after 
treatment, therefore no other surgical treatment or additional radiosurgery should be 
considered within that period unless there is unequivocal evidence of tumor enlargement 
and progressive elevation of HGH and ILGF-1. 
7.2.2 Cushing’s disease 
Cushing’s disease is one of the most devastating pituitary disorders, and is associated with 
significant morbidity and premature death. Even after transsphenoidal surgery, up to 30% 
of patients may have persistent o recurrent disease (Ciric et al., 1997; Laws & Thapar, 1996; 
Mampalam et al., 1988). Most centers define an endocrine remission as a urine free-cortisol 
(UFC) level in the normal range associated with the resolution of clinical stigmata or a series 
of normal post-operative serum cortisol levels obtained throughout the day (Nieman, 2002; 
Sheehan et al., 2000). We have treated ten patients with Cushing’s disease, with 40% of 
patients achieving normalization of hormones levels with a mean margin dose of 20.7Gy. 
The rate of remission statistically correlated with tumor volume, but not with tumor 
invasion into the cavernous sinus or the suprasellar region. 
In our experience, the rate of hormone normalization after radiosurgery for Cushing’s 
disease is difficult to predict, with remission occurring as early as 17months and as late as 
five years after LINAC Radiosurgery. Most patients who have remission, however, will do 
so within the first 2-3 years following radiosurgery. Patients with persistent disease should 
thus consider alternative treatments such as repeat TSS, or repeat radiosurgery (although 
this may be associated with a higher rate of cranial nerve damage) (Jagannathan et al., 2007). 
Published endocrine remission rates following radiosurgery (Table 4) vary considerably, 
from 10% to 100%, with higher remission rates when radiosurgery follows surgical 
debulking (Arnaldi et al., 2003; Chu et al., 2001; Izawa et al., 2000; Jackson & Noren, 1999;  
 
Author and Year
RSx 
Unit 
Pt No
F/U 
(mos)
Peripheral 
Dose (Gy) 
Hormone 
Normalization (%) 
Tumor 
Control (%) 
Laws 1999 LINAC 50 --- 22 58 --- 
Izawa 2000 GK 12 28 22 17 94 
Sheehan 2000 GK 43 44 20 63 100 
Hoybye 2001 LINAC 18 204 --- 83 83 
Kobayashi 2003 --- 20 64 29 35 100 
Devin 2004 GK 35 42 15 49 91 
Castinetti 2007 GK 40 55 29.5 42 100 
Jagannathan 
2007 
GK 90 45 25 42 100 
Brau 2011* LINAC 10 50 20.7 40 90 
Table 4. Summary of cases involving Radiosurgery in patients with Cushing’s disease. 
(*Unpublished manuscript in writing) 
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Jagannathan et al., 2007; Kobayashi et al., 2002; Morange-Ramos et al., 1998; Petrovich et al., 
2003; Witt et al., 1998). In series with at least ten patients and a median follow-up of 2 years, 
endocrine remission rates range from 17% to 83% (Kobayashi et al., 2002; Mahmoud-Ahmed 
& Suh, 2002; Morange-Ramos et al., 1998, Petrovich et al., 2003). Rähn and associates 
(Flickenger et al., 1992) reported their experience at the Karolinska Institute involving 59 
patients with Cushing’s disease who were treated using the Gamma Knife and followed for 
2–15 years. The efficacy rate of the initial treatment was 50%, with retreatment eventually 
providing normalization of cortisol production in 76% of patients (Rahn et al, 1980). 
7.2.3 Prolactin-secreting adenomas 
We use radiosurgery as a treatment for prolactinomas after failure of medical and/or 
surgical treatment. Ideally most of the prolactinomas should be treated with medication. 
Prolactinomas tumor control with medications has been reported around 80-90% (Ferone et 
al., 2007). Despite having good control, some patients do not tolerate the medications due to 
side effects and other turnout to be allergic to it.  
In our series two patients were treated as primary therapy for medical reasons. Most of the 
patients were treated following microsurgery. Of the seven patients treated at our 
institution, complete normalization of prolactin levels occurred in only 14.2%, at an average 
time of 22 months, with a mean prescription dose of 18.7Gy. Tumor control was achieved in 
100% of the cases, but did not correlate with hormone remission. 
In published studies of radiosurgery for prolactinomas, the mean prescription dose has 
varied from 13.3 Gy to 33 Gy, and remission rates varied from 0% to 84% (Table 5) (Kim et 
al., 1999, 2007; Landolt & Lomax, 2000; Laws & Vance, 1999; Post & Habas, 1990; Pouratian 
et al., 2006; Yildiz et al., 1999). Variations in success rate are likely related to the dose 
delivered to the tumor as well as other factors. Witt et al. noted no remissions with a 
prescription dose of 19 Gy (Witt et al., 1998; Witt, 2003). Pan et al. (Pan et al., 2000) reported 
a 52% endocrine ‘‘cure’’ rate in a retrospective study of 128 patients in whom GKRS was 
used as first-line treatment for prolactinomas with a prescription dose of 30 Gy. This study 
is on a large sample size, and is interesting in that GKRS was used as a first-line treatment 
before medical therapy. 
 
Author and 
Year 
RSx 
Unit 
Pt No
F/U 
(mos) 
Peripheral 
Dose (Gy) 
Hormone 
Normalization (%) 
Tumor 
Control (%) 
Mitsumori 1998 LINAC 4 47 15 0 100 
Yoon 1998 LINAC 11 49 17 84 96 
Mokry 1999 GK 21 31 14 21 NR 
Pan 2000 GK 128 33 31.5 52 98.4 
Choi 2003 GK 21 42.5 28.5 24 100 
Muramatsu 
2003 
LINAC 1 30 15 0 100 
Pouratian 2006 GK 23 58 18.6 24 89 
Brau 2011* LINAC 7 35.7 18.7 14.2 100 
Table 5. Summary of cases involving Radiosurgery in patients with prolactinomas. 
(*Unpublished manuscript in writing) 
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7.2.4 Nelson’s syndrome 
Compared with nonfunctioning and other functioning pituitary adenomas, much less 
information is available about the efficacy of stereotactic radiosurgery for the treatment of 
Nelson syndrome. A subset of Cushing’s patients do not achieve hormone normalization 
following microsurgery and radiosurgery, and undergo adrenalectomy as a ‘‘salvage’’ 
treatment for their disease. Although adrenalectomy is the definitive treatment for cortisol 
overproduction, a subset of patients may develop Nelson’s syndrome, characterized by 
rapid adenoma growth, hyper-pigmentation and tumor invasion into the parasellar 
structures (Nagesser et al., 2000). This is thought to be related to the lack of feedback on the 
hypothalamus and the pituitary gland by the lack of cortisol. 
 
Author and 
Year 
RSx 
Unit 
Pt No 
F/U 
(mos) 
Peripheral 
Dose (Gy)
Hormone 
Normalization (%) 
Tumor   
Control (%) 
Ganz 1993 GKS 3 18 NR 0 100 
Wolffenbuttel 
1998 
GKS 1 33 12 0 100 
Kobayashi 2002 GKS 6 63 28.7 33 100 
Pollock 2002 GKS 11 37 20 24 82 
Vogues 2006 LINAC 9 63/47a 15.3 16.7 89 
Mauerman 2007 GKS 23 20/50a 25 17/60b 91 
Table 6. Endocrine and radiographic outcomes of GKRS for Nelson’s syndrome. (a) Mean 
imaging follow-up/mean endocrine follow-up (b)ACTH levels decreased/ACTH reduced 
to normal values (50 pg/ml)  
Pollock and Young reported on 11 patients who underwent GKRS for Nelson’s syndrome. 
They reported control of tumor growth in 9 of 11 patients, with ACTH normalization in four 
patients (36%) (Pollock & Young, 2002).  
There are relatively few studies detailing the results of radiosurgery for Nelson’s syndrome 
(Table 6) ( Ganz, 2000; Ganz et al., 1993; Kobayashi et al., 2002; Laws & Vance, 1999; Levy et 
al., 1991; Mauermann et al., 2007; Pollock & Wolffenbuttel et al., 1998; Young, 2002). These 
studies report a mean tumor dose from between 12 Gy to 28.7 Gy, and an endocrine 
remission rate ranging from 0% to 36%, although only a minority of these studies defined 
what was meant by endocrine remission. Even cases where endocrine remission was not 
achieved, tumor growth control rates were favorable, ranging from 82% to 100%. 
8. Complications following radiosurgery for pituitary adenomas 
As previously stated, the most common problem after radiosurgery is development of 
hypopituitarism. Several groups have reported a low incidence (0–36%) of pituitary 
dysfunction following radiosurgery (Jagannathan et al., 2007; Jane et al., 2003; Sheehan et al., 
2006; Pollock et al., 1994). This incidence is likely higher when patients are followed long-
term, with the Karolinska Institute reporting a 72% incidence of hypopituitarism when 
patients were followed over 10 years (Hoybye et al., 2001). We have observed an overall risk 
of 20–30% for development of new hormone deficiency following radiosurgery without a 
significant difference across tumor pathologies. Recent studies using the Cyberknife for 
secretory adenomas, points to a significantly lower (9.5%) rate of endocrinopathy, although 
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these studies are limited by follow-up of 12 months and less in some cases (Adler et al., 
2006; Kajiwara et al., 2005; Pham et al., 2004).  
Ultimately, total dose prescribed and the prescription (margin) doses are likely the major 
factors determining the risk and onset of radiation induced hypopituitarism. The sequence 
of hormone loss following pituitary radiosurgery is unknown. The difficulty with 
determining the exact incidence of radiosurgery-induced hypopituitarism stems in part 
from the fact that many of the patients have previously undergone resection and some 
fractionated radiotherapy. In addition, pituitary deficiencies may results in part from aging. 
Thus, it is likely that hypopituitarism in the post-radiosurgical population is multifactorial 
in cause and related to radiosurgery as well as age-related changes and previous treatments 
(for example, microsurgery and radiotherapy). In spite of this, however, some have argued 
that the GH axis is the most sensitive to the late effects of radiation, with the radiation 
induced defect likely occurring at the hypothalamic level (Blacklay et al., 1986; Shalet, 1993). 
The gonadotropin and corticotrophin axes are also thought to be sensitive to radiation 
damage. Diabetes insipidus appears to be uncommon after radiosurgery with only sporadic 
case reports (Piedra et al., 2004). A well-controlled, long-term study focusing on this issue is 
needed to determine definitively the incidence of radiosurgery-induced hypopituitarism. 
Cranial neuropathies following radiosurgery are exceedingly rare following the first 
procedure, although the incidence may increase on re-treatment (Jagannathan et al., 2007). 
Visual injury in general can be avoided if the dose to the optic apparatus is restricted to less 
than 8 Gy (see previous discussion). 
Injury to the cavernous segment of the carotid artery or brain parenchyma is uncommon 
following radiosurgery. Pollock and associates have recommended that the prescription 
dose should be limited to less than 50% of the intracavernous CA vessel diameter (Pollock & 
Carpenter, 2003). Shin recommended restricting the dose to the internal CA to less than 30 
Gy (Shin et al., 2000).  
Parenchymal brain injury can be present especially in the hypothalamic and temporal 
regions. Patients with injuries to medial temporal lobes can present with complex partial 
seizures or if the injury is bilateral with recent memory impairment. Induction of cavernous 
malformations following radiosurgery to the sellar region is also theoretically possible but 
thus far has not been reported. 
The exact incidence of radiosurgical-induced neoplasm is unknown at present, although we 
have not seen one in our series of pituitary patients treated with m-LINAC system. Loeffler 
and colleagues recently reported on 6 patients, including 2 patients with pituitary adenomas 
who developed new tumors following radiosurgery (Loeffler et al., 2003). They concluded 
that although the risk of new tumor formation after radiosurgery appears to be significantly 
less than that seen following fractionated radiotherapy, new tumors can develop in the full 
dose region as well as in the low-dose periphery of the radiosurgical field. The latency to 
new tumor formation in this small series (between 6 years and 20 years) was similar to that 
seen after conventional radiation therapy. 
9. Prognosis and follow-up 
Prognosis for pituitary adenoma patients is largely dependent upon the adenoma size and 
functionality as well as the patients’ pre-radiosurgical status. Patients being treated for 
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pituitary adenomas must be followed long-term with serial clinical, ophthalmological, 
endocrine and radiological evaluations.  
Serial visual field examinations and hormonal screening should be performed. In the 
majority of cases serial testing of adrenal, thyroid function and GH reserves may be 
required as well. Patients receiving hormone replacement should have their replacement 
therapy adjusted as necessary. 
Finally, serial MR imaging should be performed to assess for tumor recurrence. It is our 
practice to perform an initial post-radiosurgical MRI at 6 months after treatment with 
follow-up MRI’s yearly thereafter, unless otherwise indicated. Endocrine and 
ophthalmologic follow-up should typically occur at the same time to provide adequate 
correlation with the treatment. There should be a good communication with every discipline 
involved in the treatment of these patients. 
10. Conclusions 
Multimodality treatment is often used to manage pituitary adenomas. Therapeutic options 
include medical management, microsurgery, radiosurgery, and radiotherapy. Except for 
prolactinomas, microsurgery remains the primary treatment for sellar lesions in surgically 
fit patients, particularly when the lesion is exerting a mass effect on the optic apparatus or 
producing hormone overproduction. Nevertheless, 20 to 50% of patients experience 
recurrence of their adenomas, and adjuvant treatment is recommended for these patients. 
Stereotactic radiosurgery has been demonstrated to be a safe and highly effective treatment 
for patients with recurrent or residual pituitary adenomas. Radiosurgery affords effective 
growth control and hormone normalization for patients and has a generally shorter latency 
period than that of fractionated radiotherapy. This shorter latency period with radiosurgery 
can typically be managed with hormone-suppressive medications. Furthermore, the 
complications (for example, radiation-induced neoplasia and cerebral vasculopathy) 
associated with radiosurgery appear to occur less frequently than those associated with 
radiotherapy. Radiosurgery may even serve as a primary treatment for those patients 
deemed unfit for microsurgical tumor removal because they have other co morbidities or 
demonstrable tumors in a surgically inaccessible location. Radiosurgery can frequently 
preserve and, at times, even restore neurological and hormone function. 
Radiosurgery is a useful tool in the treatment of both secretory and non-secretory pituitary 
adenomas. In most patients, radiosurgery controls adenoma growth. However, 
normalization of hormone overproduction can vary considerably depending on the patients’ 
presenting condition. Challenges for the future include delineating the optimal timing for 
the administration of antisecretory medications and identifying factors that can improve the 
response of pituitary adenomas to radiosurgery. Finally, physicians caring for patients with 
pituitary disorders should establish uniform endocrinological criteria and diagnostic testing 
for pre- and post-radiosurgical evaluations. 
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